Pre-Register for COVID Vaccines

Danny Stock
Update as of May 7, 9:30 AM:
An extension of the FDA’s emergency use authorization for Pfizer to children age 12+ appears imminent. That means that very soon all children age 12 and older will be eligible to get a vaccine. See additional updates below.

Use the CDC's site to find vaccination providers near you, such as pharmacies, hospitals, community vaccination and health centers, and physician offices. You can also text your zip code to 438829, or call 1-800-232-0233 to find locations near you.

Want to schedule with your state or local government? Learn more:


As April 12, all DC, MD, and VA residents age 16 and older are eligible to pre-register for a COVID-19 vaccine. GDS highly encourages everyone in our community to get vaccinated, including our eligible High School students.

It's time to pre-register!

High School students age 16 and older should pre-register to receive a COVID vaccine now.

Please share your child(ren)’s vaccination information with the School. Upon vaccination, please upload a copy of your child’s vaccination card to the immunization section of your child(ren)'s Magnus Health account (access your account via the MyGDS Health resource board). This helps us in determining the need to quarantine and setting a return-to-school date. 

You may be wondering when children under the age of 16 will be eligible for vaccines. 

  • Pfizer is the only vaccine currently approved for children age 16 and older—under the FDA's emergency use authorization (EUA) as of December 11, 2020. The Moderna vaccine (EUA: 12/18/20) and Johnson & Johnson vaccine (EUA: 2/27/21) are currently only approved for 18 and older.
  • Trials continue for all three vaccines for younger children. There is no specific date when vaccines will be available to children, but experts estimate those below age 16 may begin getting vaccinated next winter.
  • Pfizer-BioNTech announced promising results from their trial of 12–15-year-olds, saying that the vaccine “demonstrated 100% efficacy and robust antibody responses, exceeding those reported in trial of vaccinated 16–25-year-old participants in an earlier analysis, and was well tolerated.” They are seeking emergency use authorization (EUA) from the FDA “with the hope of starting to vaccinate this age group before the start of the next school year.”

Finally, a note about vaccine efficacy from LMS nurse Elizabeth McDermott, particularly in light of confusing media takes on the effectiveness and availability of the three vaccines currently available:

"The important data for us to focus on is that all three vaccines have been almost 100% effective in preventing death and hospitalization! That is amazing efficacy! Do not wait for the perfect vaccine. I think we can all agree that a mild case of COVID is better than hospitalization and/or death. Please take whatever vaccine is offered to you and encourage others to do the same."

Please pre-register now.

  • High School